In vivo, cyclosporins are rapidly and almost completely converted to metabolites. AM1 and AM4N, primary metabolites of CsA, mediated inhibition of transport, as did CsG metabolites GM1, GM4N and GM9. AM1 and GM9 are known to reach steady-state in vivo levels that exceed the inhibitory concentration identified here by 1.1-to 1.9-fold. Thus, cyclosporin metabolites, which accumulate in the blood during infusion of CsA and other cyclosporins, are shown here to be effective chemosensitizers for normally drugresistant myeloma cells in vitro. Cyclosporin metabolites are considered to be less toxic than the parent drugs, suggesting that novel chemosensitization strategies designed to minimize concentrations of parent drug and maximize accumulation of primary metabolites in vivo may optimize cytotoxicity to the malignant clone in myeloma.
Introduction
In multiple myeloma (MM), studies have been aimed at overcoming drug resistance with chemosensitizers or resistance modifiers, compounds that interfere with the ability of cellular transporters, including p-glycoprotein 170, to exclude drugs. [1] [2] [3] To date, these have met with only limited success in eradication of the malignant clone in myeloma and the use of drug resistance modifiers is controversial. 4 Although initially bone marrow (BM) plasma cells in myeloma appear to be Correspondence: LM Pilarski, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada T6G1Z2; Fax: 403 432 8928 Received 27 November 1997; accepted 6 January 1998 effectively depleted by chemotherapy in the majority of patients, circulating clonal B cells persist. 5, 6 Consistent with this pattern in vivo, circulating myeloma B cells exhibit active drug or dye export in vitro, but BM plasma cells exhibit compromised export with consequent drug/dye retention in untreated as well as previously treated patients. 5 The use of chemotherapy to eradicate the malignant clone in myeloma is compromised by the ability of some malignant cells to exclude or export chemotherapeutic drugs, thus rendering them drug resistant. 5, [7] [8] [9] A variety of transporter and drug exclusion mechanisms mediate resistance to anti-cancer drugs (reviewed in Ref. 10) , including p-glycoprotein 170 [10] [11] [12] and the multi-drug related protein (mrp). 13, 14 Transport of chemotherapeutic drugs such as doxorubicin and vinca alkaloids is inhibited by cyclosporin A (CsA) and its nonimmunosuppressive derivative PSC 833. However, the majority of work underlying assessment of the inhibitory concentrations for chemosensitizers is based on data from drugresistant cell lines. Thus, there is a need to evaluate their effects on P-gp function of ex vivo cells from patients with malignancies. 4 A significant concern in the use of chemosensitizers is the fact that p-glycoprotein 170 plays a role in the biology of many normal tissues including the endothelial lining of blood vessels, the placenta, uterus, adrenals, hematopoietic stem cells and lymphocytes. [15] [16] [17] [18] [19] [20] Efficient inhibition of this and other transporters might thus be predicted to result in adverse effects. The aim of chemosensitization is to maximize inhibition of drug transport and consequent damage to malignant cells, while minimizing its impact on transporter function carried out by normal cells.
The objective of this study was to evaluate the role of cyclosporin analogues and their metabolites in the inhibition of dye transport by ex vivo cells from myeloma patients or normal donors. In vivo, cyclosporins are rapidly converted to a number of metabolites, some of whose total concentration exceeds that of the parent drug in the circulation, indicating significant exposure of blood and tissue to these biotransformation products. [21] [22] [23] For the most part, these metabolites have minimal immunosuppressive activity and toxicity in comparison with the parent drug. [21] [22] [23] A number of CsA analogues have been produced including CsG, an immunosuppressive natural variant of CsA. PSC 833, a non-immunosuppressive cyclosporin is currently being tested as a chemosensitizer in myeloma and other malignancies. 3, 10 In this study we show that for ex vivo myeloma cells, CsA, PSC 833, CsG or SDZ 280-446, a semisynthetic cyclopeptolide, 24, 25 and some primary CsA and CsG metabolites effectively inhibit P-gp at concentrations expected to be achieved during in vivo infusion of chemosensitizers.
Materials and methods

Patient tissue
Peripheral blood was obtained from 164 patients with multiple myeloma after informed consent, including 24 at diagnosis, 65 during intermittent chemotherapy and 69 after cessation of chemotherapy. Peripheral blood from normal donors was obtained through the Edmonton Red Cross Blood Transfusion Service. Peripheral blood mononuclear cells (PBMC) were purified by centrifugation over Ficoll-Paque (Pharmacia, Dorval QC, Canada) as previously described. 5, 6 Human thymocytes were from discarded tissue obtained after pediatric cardiac surgery at the University of Alberta Hospital.
Antibodies
Leu15-PE (CD11b) and Leu4-PE (CD3) were from Becton Dickinson (San Jose, CA, USA). FMC63 (CD19) was conjugated to PE. Isotype-matched control antibodies were from Southern Biotech (Birmingham, AL, USA).
Reagents
Rhodamine 123 (Rh123) was from Molecular Probes (Seattle, WA, USA). CsA, CsG, PSC 833, dansyl CsA and SDZ 280-446 were donated by Sandoz Pharma (Basel, Switzerland). CsA and CsG metabolites were purified from urine of renal transplant patients receiving the drug as part of their immunosuppressive therapy, as previously described. 22, 26 The structure and purity of these metabolites was confirmed by Fast Atom Bombardment Mass Spectroscopy and 13 C nuclear magnetic resonance. The purity of all metabolites was Ͼ97%.
Immunofluorescence Two-color fluorescence staining was used for the study of surface marker expression as previously described. 6 Samples were analyzed using a FACScan (Becton Dickinson). Each mAb was compared to its appropriate isotype-specific control.
In situ RT-PCR MM PBMC were sorted as indicated in results and placed on slides for in situ RT-PCR as extensively described elsewhere. 5, 6 Primer sequences were previously described. 5, 6 IgH VDJ transcripts were detected using consensus primers to FR2 and Jh. 6, 27 Rh123 dye efflux
The ability of cells to minimize retention of the mitochondrialbinding dye Rh123 was as previously described. 5 Blocking agents were CsA analogues/derivatives and their metabolites as indicated in Results. Inhibitors were used at 1 g/ml unless otherwise indicated. Cells were then stained with a direct phycoerythrin (PE) conjugate of mAb CD11b, with the blocking agent included in all buffers for the samples treated with it, washed, resuspended in PBS with or without the blocking agent and run immediately on the FACScan (Becton Table 1 MM blood B cells have CsA sensitive dye efflux % of CD11b + B cells effluxing Rh123 % of total PBMC expressing CD19 and CD11b 23 ± 2 % of B cells exporting dye in the absence of 65 ± 2 CsA % of B cells exporting dye in the presence of 9 ± 1 CsA MM PBMC from 81 patients were loaded with Rh123, allowed to efflux for 3 h with or without CsA (1 g/ml), followed by staining with the indicated CD11b-PE as indicated in Methods. The number of Rh124 dim cells was used as the measure of cells effluxing Rh123.
Dickinson). All efflux assays were performed immediately after purification on the day of sample collection.
Results
Circulating malignant B cells in myeloma export Rh123
B cells from MM PBMC expressing CD34 and CD11b have been previously shown to be the predominant clonotypic subset of B cells, and to be clonally identical to autologous plasma cells in MM. 5, 6 CD11b + MM B cells transport dye and drug, 5 suggesting they may also be a primary reservoir of malignant disease in MM. Myeloma PBMC were loaded with Rh123 and allowed to export the dye, followed by staining with mAbs to identify malignant B cells. A series of 81 patients were analyzed for transporter function (Rh123 export) in the presence or absence of cyclosporin A (CsA) ( Table 1) . Malignant B cells in MM are distinguished from residual normal B cells by their expression of CD11b. 5 We confirm here that the majority of CD11b + MM B cells exhibited CsA-sensitive Rh123 export ( The ability of cyclosporins and their metabolites to inhibit Rh123 export was compared to CsA, over a concentration range of 0.01-1.0 g/ml (Table 3) . For CsA, the lowest concentration required to impose inhibition of at least 30% (within the range of 30-60%) varied from 0.03-0.3 g/ml for B cells from individual MM donors. For malignant MM blood B cells, inhibition of transporter activity by PSC 833 was approximately three times more efficient than CsA (Table 3) . Inhibition by CsG was approximately three to five times more effective for MM blood B cells was CsA (Table 3) . By comparison, for B cells from normal donors, CsG was comparable to CsA in inhibitory activity (Table 3) . A semi-synthetic cyclic peptolide, SDZ 280-446, efficiently inhibited Rh123 export by MM blood B cells, comparable to that by CsA, PSC 833 and CsG. SDZ 280-446 did not reliably inhibit dye transport by normal B cells (Table 3) . SDZ 280-446 was at least 10-fold more efficient an inhibitor of MM blood B cells than it was for B cells from normal donors.
Primary CsA and CsG metabolites inhibit transport by MM blood B cells
Cyclosporins are extensively metabolized in the liver and other tissues. The primary metabolites for CsA are termed AM1, AM9 and AM4N and for CsG GM1, GM9 and GM4N, some of which reach concentrations equal to or exceeding that of the parent drug by 12 h post administration. 21, 29 These are further converted to secondary metabolites. The immunosuppressive activity of these metabolites decreases with increasing polarity from the parent drug, and all primary metabolites have some activity. 21 During chemosensitization, cyclosporins will be metabolized prior to their excretion. The potential contributory role of metabolites in overcoming drug export is unknown. The ability of primary and secondary metabolites to inhibit dye transport by malignant MM blood B cells was evaluated (Table 3) . Of the CsA primary metabolites, only AM1 and AM4N mediated inhibition of dye transport (Table 3) , at concentrations about four times higher than that required for the parent drug. AM9 mediated only partial inhibition at 1 g/ml for 1/4 MM PBMC tested. Secondary CsA metabolites had no inhibitory activity (Table 3 , lines 8-11). All of the CsG primary metabolites, GM1, GM4N and GM9, were inhibitory for dye transport by MM blood B cells ( Table 3 ). The secondary metabolite GM19 had no detectable inhibition of P-gp. Metabolites of PSC 833 were not available for evaluation.
Predicted potency of cyclosporin analogues, derivatives and metabolites in vivo
In order to predict the effects of these agents in vivo, one needs to consider the inhibitory concentration in vitro and the steadystate concentration achieved in vivo. Following oral use or intravenous infusion, some cyclosporin metabolites are present in circulation at steady-state concentrations equal to or exceeding that of the parent drug. Their predicted potency in vivo is a function of their ability to inhibit transport in vitro and their concentration at steady state relative to the parent drug in vivo. The hypothetical steady-state levels in cancer patients were extrapolated from the extensive studies on cyclosporin metabolites in transplant patients. [21] [22] [23] 29 The calculations in Figure 1 predict the extent to which the steady-state levels in vivo exceed the concentrations required to inhibit malignant B cells in vitro. For cyclosporin analogues and derivatives, this value was 4-20, indicating that in vivo steadystate concentrations are likely to considerably exceed the amount required for inhibition of P-gp on ex vivo MM B cells. Of the metabolites, only AM1 and GM9 had predicted in vivo steady-state levels that exceeded the inhibitory concentration identified in vitro.
Discussion
In multiple myeloma, CsA, CsG, PSC 833, and the novel peptolide SDZ 280-446 inhibit drug export function of malignant clonotypic B cells. We show here that some of the in vivo metabolites of CsA and CsG also have inhibitory function, and thus may play a significant role in chemosensitization by these and related compounds. CsA, PSC 833 and CsG inhibit transporter function by ex vivo MM blood B cells at concentrations within the range clinically achieved in plasma. [2] [3] [4] The synthetic peptolide SDZ 280-446 mediated 10-fold more efficient inhibition of MM B cells than it did for normal B cells, suggesting the possibility for selective activity in vivo. PSC 833 and CsG had equivalent inhibitory capacity for both malignant and normal B cells, while CsA preferentially inhibited dye export by normal B cells as compared to malignant B cells. Primary metabolites of CsA and CsG also inhibited dye transport by Relative predicted potency of CsA analogues and metabolites as compared to CsA. The extent to which steady-state concentrations of CsA derivatives and metabolites exceeded the inhibitory concentration identified in vitro was calculated as follows: Their reduced toxicity and immunosuppression, and relatively high steady-state concentration in whole blood, 21, 22, 26, 29 suggests that metabolites of cyclosporins being used clinically may play a significant role in chemosensitization in vivo.
The majority of bone marrow-resident plasma cells in myeloma, for patients at all stages of disease, lack detectable export function, since they retain both Rh123 dye and doxorubicin. 5, 7 In contrast, circulating B cells in MM have efficient dye and drug export. 5, 7, 20 Clinically, this is supported by observations that BM plasma cells are largely depleted by successful chemotherapy while circulating B cells persist. 6, 7, 20, 27 We have demonstrated that the majority of the circulating B cells in MM express an IgH rearrangement identical to that of autologous BM plasma cells (Szczepek AJ, Seeberger K, Wisniak J, Mant MJ, Belch AR, Pilarski LM. A high frequency of circulating clonotypic B cells in the blood of patients with multiple myeloma as measured by single cell and in situ RT-PCR (submitted)), 5, 6 providing an unequivocal marker for the malignant clone and establishing the relevance of their drug resistance properties to treatment protocols. This work indicates that concentration of inhibitor required to mediate maximal inhibition of dye export by clonotypic MM B cells is exceeded 4-to 20-fold by the steady-state levels achieved in vivo. [2] [3] [4] In conclusion, the levels of CsA or PSC 833 that have been reported after continuous infusion or oral administration [2] [3] [4] are sufficient to inhibit transporter function ex vivo of malignant B cells in myeloma. Since the primary metabolites of CsA are considered to be less toxic and have reduced immunosuppressive activity compared to the parent CsA, this work suggests the modification of chemosensitization protocols in order to minimize concentrations of parent drug and maximize that of primary metabolites. In this regard, it may be significant that diltiazem, a calcium channel blocker, inhibits conversion of CsA primary metabolites to the secondary forms, 30 thus maximizing the concentrations of the inhibitory primary metabolites. Alternatively, the evaluation of selected synthetic metabolites might be beneficial. Circulating malignant B cells appear to be a reservoir of drug-resistant malignant disease in multiple myeloma. This work suggests that it may be clinically beneficial to maximize the steady-state concentration of primary cyclosporin metabolites that have reduced toxicity but retain the ability to inhibit drug export by otherwise drug-resistant members of the malignant clone in myeloma as well as in other cancers.
